Table 1.
Characteristics of patients with small-bowel mucosal injuries per study group (polaprezinc treatment and no polaprezinc treatment, i.e., control)
| Characteristic | Polaprezinc (n = 10) | Control (n = 10) | P value |
|---|---|---|---|
| Sex ratio (male/female) |
9/1 |
7/3 |
N.S.* |
| Age (years); median (range) |
78.5 (64-82) |
75.5 (62-86) |
N.S.** |
| Hemoglobin concentration (g/dL); median (range) |
13.6 (10.2-15.3) |
13.7 (8-15) |
N.S.** |
| Indication for low-dose aspirin therapy |
|
|
|
| Valvular heart disease |
3 |
2 |
|
| Stroke |
3 |
7 |
N.S.* |
| Other |
4 |
1 |
|
| Duration of low-dose aspirin (months); median (range) |
64.5 (24-120) |
48 (36-120) |
N.S.** |
| Anti-ulcer drug |
|
|
|
| H2 blocker |
1 |
2 |
N.S.* |
| PPI |
3 |
1 |
|
| None |
6 |
7 |
|
| Initial CE findings |
|
|
|
| Median number of erosions/ulcers (range) |
2 (0-6) |
2 (0-10) |
N.S.** |
| Median number of reddened lesions (range) |
3 (0-7) |
2 (0-7) |
N.S.** |
| CE score |
|
|
|
| Median score (range) |
180 (0-450) |
225 (0-225) |
N.S.** |
| CE score by category |
|
|
|
| Normal or clinically insignificant change (<135) |
3 |
4 |
|
| Mild change (≥135 and <790) |
7 |
6 |
N.S.* |
| Moderate or severe change (≥790) | 0 | 0 |
Number of patients are shown unless otherwise indicated.
*by Fisher’s exact test **by Wilcoxon test.
Abbreviations: CE, Capsule endoscopy; PPI, Proton pump inhibitor; N.S., Not significant.